» Articles » PMID: 28244639

Selective Elimination of Neuroblastoma Cells by Synergistic Effect of Akt Kinase Inhibitor and Tetrathiomolybdate

Overview
Journal J Cell Mol Med
Date 2017 Mar 1
PMID 28244639
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroblastoma is the most common extracranial solid tumour of infancy. Pathological activation of glucose consumption, glycolysis and glycolysis-activating Akt kinase occur frequently in neuroblastoma cells, and these changes correlate with poor prognosis of patients. Therefore, several inhibitors of glucose utilization and the Akt kinase activity are in preclinical trials as potential anti-cancer drugs. However, metabolic plasticity of cancer cells might undermine efficacy of this approach. In this work, we identified oxidative phosphorylation as compensatory mechanism preserving viability of neuroblastoma cells with inhibited glucose uptake/Akt kinase. It was oxidative phosphorylation that maintained intracellular level of ATP and proliferative capacity of these cells. The oxidative phosphorylation inhibitors (rotenone, tetrathiomolybdate) synergized with inhibitor of the Akt kinase/glucose uptake in down-regulation of both viability of neuroblastoma cells and clonogenic potential of cells forming neuroblastoma spheroids. Interestingly, tetrathiomolybdate acted as highly specific inhibitor of oxygen consumption and activator of lactate production in neuroblastoma cells, but not in normal fibroblasts and neuronal cells. Moreover, the reducing effect of tetrathiomolybdate on cell viability and the level of ATP in the cells with inhibited Akt kinase/glucose uptake was also selective for neuroblastoma cells. Therefore, efficient elimination of neuroblastoma cells requires inhibition of both glucose uptake/Akt kinase and oxidative phosphorylation activities. The use of tetrathiomolybdate as a mitochondrial inhibitor contributes to selectivity of this combined treatment, preferentially targeting neuroblastoma cells.

Citing Articles

Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells.

Adamova B, rihova K, Pokludova J, Benes P, Smarda J, Navratilova J J Cell Mol Med. 2022; 27(1):76-88.

PMID: 36523175 PMC: 9806293. DOI: 10.1111/jcmm.17636.


Dual specificity phosphatase 7 drives the formation of cardiac mesoderm in mouse embryonic stem cells.

Sladecek S, Radaszkiewicz K, Bohmova M, Gybel T, Radaszkiewicz T, Pachernik J PLoS One. 2022; 17(10):e0275860.

PMID: 36227898 PMC: 9560500. DOI: 10.1371/journal.pone.0275860.


Lactic Acidosis Interferes With Toxicity of Perifosine to Colorectal Cancer Spheroids: Multimodal Imaging Analysis.

Pavlatovska B, Machalkova M, Brisudova P, Pruska A, Stepka K, Michalek J Front Oncol. 2020; 10:581365.

PMID: 33344237 PMC: 7746961. DOI: 10.3389/fonc.2020.581365.


Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?.

Xu Y, Xue D, Bankhead 3rd A, Neamati N J Med Chem. 2020; 63(23):14276-14307.

PMID: 33103432 PMC: 9298160. DOI: 10.1021/acs.jmedchem.0c01013.


Developing preclinical models of neuroblastoma: driving therapeutic testing.

Ornell K, Coburn J BMC Biomed Eng. 2020; 1:33.

PMID: 32903387 PMC: 7422585. DOI: 10.1186/s42490-019-0034-8.


References
1.
Choo A, Kim S, Vander Heiden M, Mahoney S, Vu H, Yoon S . Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell. 2010; 38(4):487-99. PMC: 2896794. DOI: 10.1016/j.molcel.2010.05.007. View

2.
Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

3.
Swerdlow R, E L, Aires D, Lu J . Glycolysis-respiration relationships in a neuroblastoma cell line. Biochim Biophys Acta. 2013; 1830(4):2891-8. PMC: 3594384. DOI: 10.1016/j.bbagen.2013.01.002. View

4.
Spix C, Pastore G, Sankila R, Stiller C, Steliarova-Foucher E . Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006; 42(13):2081-91. DOI: 10.1016/j.ejca.2006.05.008. View

5.
Matthay K, Reynolds C, Seeger R, Shimada H, Adkins E, Haas-Kogan D . Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009; 27(7):1007-13. PMC: 2738615. DOI: 10.1200/JCO.2007.13.8925. View